Chronic fatigue syndrome (Myalgic Encephalomyelitis) is a disorder that causes extreme long lasting fatigue that limits your ability to do ordinary daily activities. Symptoms may include fatigue for 6 months or more and experiencing other problems such as muscle pain, memory problems, headaches, pain in multiple joints, sleep problems, sore throat and tender lymph nodes. The cause of chronic fatigue syndrome is unknown. There is no cure for chronic fatigue syndrome so the goal of treatment is to improve symptoms. Medicines may treat pain, sleep disorders and other problems.
New research findings may shed new light on the potential cause of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment.
Routledge Journals is pleased to announce a new Special Issue from the Journal of Prevention & Intervention in the Community exploring topics and constructs that could help clarify uncertainties surrounding Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), or Myalgic Encephalomyelitis (ME) research.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome -- commonly referred to as ME/CFS -- is a legitimate, serious, and complex systemic disease that frequently and dramatically limits the activities of affected individuals, says a new report from the Institute of Medicine.
Reducing fears that exercise or activity will make symptoms worse is one of the most important factors determining the success of cognitive behaviour therapy (CBT) or graded exercise therapy (GET) in reducing fatigue and improving physical function in people with chronic fatigue syndrome (CFS), according to new analysis of data from the PACE trial, reported in The Lancet Psychiatry journal.
A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.
Providing increased services for Chronic Fatigue Syndrome sufferers will be the focus of Griffith research following the award of a $1.85m grant to one of Australia’s foremost authorities on the condition.
Sufferers of Chronic Fatigue Syndrome are set to benefit with the dual launch of a specialist Griffith University clinic and smartphone app, both aimed to manage their illness and improve health outcomes.
Researchers at the RIKEN Center for Life Science Technologies, in collaboration with Osaka City University and Kansai University of Welfare Sciences, have used functional PET imaging to show that levels of neuroinflammation, or inflammation of the nervous system, are higher in patients with chronic fatigue syndrome than in healthy people.
People living with chronic fatigue are set to benefit with the opening next week (Dec 2), of the National Centre for Neuroimmunology and Emerging Diseases at Griffith University.
PANDORA Org and other patient organizations say a recent report from the U.S. Food and Drug Administration (FDA) shows the agency must take further action to open up opportunities for ME/CFS drug development.
Fibromyalgia is a common disorder that is diagnosed in people who have pain in many areas of their body together with important symptoms such as...
With peer-reviewed articles on fatigue having increased 90% over the past decade - and nearly 1,000 papers on the topic published in 2011 alone - the time is right for Routledge's new journal, Fatigue: Biomedicine, Health & Behavior.
Nova Southeastern University's College of Osteopathic Medicine (NSU-COM) will hold a grand opening for America's first Institute for Neuro Immune Medicine on Feb. 12.
Research led by Queen Mary, University of London, has shown that recovery from chronic fatigue syndrome (CFS) is possible for some patients, and has identified two treatments most likely to lead to recovery.
Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).
Nova Southeastern University (NSU) will be hosting a conference on Saturday, Jan. 26 about the upcoming opening of the NSU College of Osteopathic Medicine's Institute for Neuro Immune Medicine.
A new study published in the current issue of Psychotherapy and Psychosomatics has examined the role of inflammation in chronic fatigue syndrome, a disorder that affects many people and does not seem to have an explanation that is likely to yield satisfactory treatment.
The causes of chronic fatigue syndrome (CFS) have long eluded scientists. In 2009, a paper in the journal Science linked the syndrome-sometimes called myalgic encephalomyelitis (ME)-to infection with a mouse retrovirus called XMRV (xenotropic murine leukemia virus (MLV)-related virus).
The International Association for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (IACFS/ME), the largest group of physicians and researchers dedicated to chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), has released updated care guidelines directed at primary care physicians and other health care providers.